Sign In
Buy CRL
$179.87
+5.08 (+2.91%)
At Close: Jun 03, 2026
Charles River Laboratories: Q2, Cost Structure Streamlining (Rating Upgrade)
09:00am, Saturday, 10'th Aug 2024
Weak biopharma market challenges persist, impacting CRL's revenue and bottom-line growth. Cost streamlining initiatives in place to generate $150 million in annualized cost savings by FY25. Growth pro
Charles River (CRL) Q2 Earnings Beat Estimates, 2024 View Down
02:30pm, Wednesday, 07'th Aug 2024
Charles River's (CRL) Manufacturing business segments report organic revenue growth, partially offset by lower revenues in the DSA and RMS segments.
Charles River Laboratories International Inc (CRL) Q2 2024 Earnings Call Transcript
02:21pm, Wednesday, 07'th Aug 2024
Charles River Laboratories International Inc (NYSE:CRL ) Q2 2024 Results Conference Call August 7, 2024 9:00 AM ET Company Participants Todd Spencer - Corporate Vice President of Investor Relations Ji
Charles River Labs Says It Expects Sales To Fall, Sending Its Stock Tumbling
01:31pm, Wednesday, 07'th Aug 2024
Shares of Charles River Laboratories (CRL) tumbled over 12% in intraday trading Wednesday after the company said it expects to post a decline in sales for the full fiscal year, instead of growth.
Here's What Key Metrics Tell Us About Charles River (CRL) Q2 Earnings
10:36am, Wednesday, 07'th Aug 2024
While the top- and bottom-line numbers for Charles River (CRL) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compa
Charles River Laboratories Stock Sinks As It Warns Of Continued Biotech Demand Slump, Lowers Forecast
10:06am, Wednesday, 07'th Aug 2024
Charles River Laboratories International Inc CRL reported second-quarter 2024 revenue of $1.03 billion on Wednesday, a decrease of 3.2% year over year, beating the consensus of $1.024 billion.
Charles River Laboratories (CRL) Surpasses Q2 Earnings and Revenue Estimates
09:11am, Wednesday, 07'th Aug 2024
Charles River Laboratories (CRL) came out with quarterly earnings of $2.80 per share, beating the Zacks Consensus Estimate of $2.39 per share. This compares to earnings of $2.69 per share a year ago.
Charles River cuts 2024 forecast as funding crunch among biotech clients persists
08:26am, Wednesday, 07'th Aug 2024
Charles River Laboratories trimmed its annual forecast on Thursday, as it no longer expects demand for its drug discovery and development services to improve in the second half of the year, sending it
Unlocking Q2 Potential of Charles River (CRL): Exploring Wall Street Estimates for Key Metrics
10:21am, Monday, 05'th Aug 2024
Get a deeper insight into the potential performance of Charles River (CRL) for the quarter ended June 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for
Here's How Charles River (CRL) is Placed Ahead of Q2 Earnings
09:45am, Wednesday, 24'th Jul 2024
Growth across Microbial Solutions and Biologics Testing and CDMO businesses is likely to have contributed to Charles River's (CRL) Q2 revenues, offset by lower biopharmaceutical demand.
Charles River Laboratories Schedules Second-Quarter 2024 Earnings Release and Conference Call
04:30pm, Tuesday, 16'th Jul 2024
WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories schedules second-quarter 2024 earnings release and conference call for Wednesday, August 7th.
SAN DIEGO, July 16, 2024 (GLOBE NEWSWIRE) -- Johnson Fistel, LLP (www.johnsonfistel.com), a shareholder rights law firm, announces its continuing investigation of whether certain directors and officer
Charles River (CRL) Teams Up to Aid Stargardt's Disease Therapy
10:41am, Tuesday, 09'th Jul 2024
Charles River (CRL) signs an agreement with AAVantgarde to produce GMP plasmid DNA for Stargardt's disease program.
Charles River to Perform Plasmid Manufacturing for AAVantgarde
08:00am, Monday, 08'th Jul 2024
WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) and AAVantgarde today announced a contract development and manufacturing organization (CDMO) agreement to
Charles River (CRL) Could be an Apt Pick Right Now: Here's Why
10:27am, Friday, 05'th Jul 2024
Investors are optimistic about Charles River (CRL) due to its business performance and strategic buyouts.
